Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$28.46−0.03 (-0.11%)
Close on Nov 18, 2026Market cap $4.54BP/E –Yield –
Adaptive Biotechnologies operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Adaptive Biotechnologies's operating income for the twelve months ending Jun 30, 2026 was -$37.46M. For fiscal 2025 it was -$57.12M. The highest annual figure on record is -$44.48M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$57.12M | – |
| FY2024 | Dec 31, 2024 | -$162.55M | – |
| FY2023 | Dec 31, 2023 | -$227.04M | – |
| FY2022 | Dec 31, 2022 | -$200.19M | – |
| FY2021 | Dec 31, 2021 | -$208.97M | – |
| FY2020 | Dec 31, 2020 | -$152.82M | – |
| FY2019 | Dec 31, 2019 | -$78.39M | – |
| FY2018 | Dec 31, 2018 | -$49.76M | – |
| FY2017 | Dec 31, 2017 | -$44.48M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.77M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.21M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.77M | – |
| Q3 FY2025 | Sep 30, 2025 | $10.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.04M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$33.84M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.63M | – |
| Q2 FY2024 | Jun 30, 2024 | -$47.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$48.76M | – |
| Q4 FY2023 | Dec 31, 2023 | -$71.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$50.96M | – |
| Q2 FY2023 | Jun 30, 2023 | -$47.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$57.19M | – |
| Q4 FY2022 | Dec 31, 2022 | -$39.19M | – |
| Q3 FY2022 | Sep 30, 2022 | -$45.43M | – |
| Q2 FY2022 | Jun 30, 2022 | -$52.50M | – |
| Q1 FY2022 | Mar 31, 2022 | -$63.07M | – |
| Q4 FY2021 | Dec 31, 2021 | -$61.60M | – |
| Q3 FY2021 | Sep 30, 2021 | -$56.33M | – |
| Q2 FY2021 | Jun 30, 2021 | -$49.77M | – |
| Q1 FY2021 | Mar 31, 2021 | -$41.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$44.24M | – |
| Q3 FY2020 | Sep 30, 2020 | -$37.05M | – |
| Q2 FY2020 | Jun 30, 2020 | -$36.91M | – |
| Q1 FY2020 | Mar 31, 2020 | -$34.62M | – |
| Q4 FY2019 | Dec 31, 2019 | -$24.19M | – |
| Q3 FY2019 | Sep 30, 2019 | -$18.05M | – |
| Q2 FY2019 | Jun 30, 2019 | -$16.11M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.05M | – |
| Q4 FY2018 | Dec 31, 2018 | -$14.14M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.16M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.31M | – |
See a number that looks wrong?